



Randomized controlled trial of vitamin D supplementation in sarcoidosis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003562
Article Type:	Research
Date Submitted by the Author:	08-Jul-2013
Complete List of Authors:	Bolland, Mark; University of Auckland, Department of Medicine Wilsher, Margaret; Auckland District Health Board, Respiratory Services Grey, Andrew; University of Auckland, Department of Medicine Horne, Anne; University of Auckland, Department of Medicine Fenwick, Sheryl; University of Auckland, Department of Medicine Gamble, Greg; University of Auckland, Department of Medicine Reid, Ian; University of Auckland, Department of Medicine
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	THORACIC MEDICINE, Clinical trials < THERAPEUTICS, Calcium & bone < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

Title: Randomized controlled trial of vitamin D supplementation in sarcoidosis.

Running title: Vitamin D supplementation and sarcoidosis

Authors:

Mark J Bolland, MBChB, PhD,¹
Margaret L Wilsher, MD,^{1,2}
Andrew Grey, MD,¹
Anne M Horne, MBChB,¹
Sheryl Fenwick, BAppSc¹
Greg D Gamble, MSc¹
Ian R Reid, MD,¹

Affiliation:

¹Department of Medicine, University of Auckland, Private Bag 92 019, Auckland 1142, New Zealand; ² Green Lane Respiratory Services, Auckland District Health Board, Private Bag 92024, Auckland 1142, New Zealand

Address for correspondence/reprints:

Mark Bolland
Bone and Joint Research Group,
Department of Medicine, University of Auckland
Private Bag 92 019, Auckland 1142, New Zealand
Email: m.bolland@auckland.ac.nz
Ph 64 9 373 7999
Fax 64 9 373 7677

Funding:

This study was funded by the Health Research Council of New Zealand, and the Greenlane Research and Education Fund.

Word counts:

Text only: 2326
Abstract: 248
Figures: 5
Tables: 2

Disclosure: All the authors state that they have no conflicts of interest.

Key words: vitamin D, hypercalcaemia, sarcoidosis, bone turnover, bone mineral density

Trial registration: This trial is registered at the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au). The registration number is ACTRN12607000364471, date of registration 5/7/2007.

Article focus:

- The effect of vitamin D supplementation on calcium homeostasis and skeletal health in sarcoidosis
- A randomized, placebo-controlled trial of vitamin D supplements in 27 patients with sarcoidosis and 25-hydroxyvitamin D <50nmol/L

Key messages:

- Vitamin D supplementation had no effect on serum or urine calcium, bone turnover markers or bone mineral density over 12 months, but caused 1 case of significant hypercalcaemia.
- This clinical trial suggests that vitamin D supplements are not beneficial and may be harmful for patients with sarcoidosis and mildly low vitamin D levels.

Limitations:

- The study had limited power to detect small differences in bone density and bone turnover markers.
- Few participants had 25-hydroxyvitamin D levels < 25 nmol/L, and therefore the findings may not apply to individuals with very low vitamin D levels.

Abstract**Background**

The role vitamin D intake/production plays in sarcoidosis-associated hypercalcaemia is uncertain. However, authoritative reviews have recommended avoiding sunlight exposure and vitamin D supplements, which might lead to adverse skeletal outcomes from vitamin D insufficiency.

Methods

We undertook a 1y randomized, placebo-controlled trial of vitamin D supplements (50,000IU weekly cholecalciferol for 4 weeks, then 50,000IU monthly for 11 months) in 27 patients with sarcoidosis and 25-hydroxyvitamin D (25OHD) <50nmol/L. The primary endpoint was the change in serum calcium over 12 months, and secondary endpoints included measurements of calcitropic hormones, bone turnover markers, and bone mineral density (BMD).

Results

The mean age of participants was 57y and 70% were female. The mean (SD) screening 25OHD was 35(12) and 38(9) nmol/L in the treatment and control groups, respectively. Vitamin D supplementation increased 25OHD to 94 nmol/L after 4 weeks, 84 nmol/L at 6 months, and 78 nmol/L at 12 months, while levels remained stable in the control group. 1,25 dihydroxyvitamin D levels were significantly different between the groups at 4 weeks, but not at 6 or 12 months. There were no between-groups differences in albumin-adjusted serum calcium, 24h urine calcium, markers of bone turnover, parathyroid hormone, or BMD over the trial. One participant developed significant hypercalcaemia after 6 weeks (total cholecalciferol dose 250,000IU).

Conclusions

In patients with sarcoidosis and 25OHD <50nmol/L, vitamin D supplements did not alter average serum calcium or urine calcium, but had no benefit on surrogate markers of skeletal health and caused one case of significant hypercalcaemia.

For peer review only

Introduction:

Hypercalcaemia occurs commonly in sarcoidosis, with an estimated prevalence of 4-11%. [1,2] Hypercalcaemia results from dysregulated production of 1,25-dihydroxyvitamin D (1,25OHD) by activated macrophages in granulomata. [3] Although the mechanism of hypercalcaemia is known, the role of vitamin D intake and production is less certain. On one hand, cases of hypercalcaemia and sarcoidosis precipitated by sunlight exposure or vitamin D supplements have been reported, [4-8] and there is seasonal variation in 1,25OHD levels [9] and the prevalence of hypercalcaemia. [7, 9, 10] These findings suggest that increases in 25-hydroxyvitamin D (25OHD) levels through sunlight exposure or vitamin D intake contribute to the hypercalcaemia. On the other hand, studies have reported no correlation between 25OHD, 1,25OHD, and serum calcium, [11] historical studies of treatment with very large doses of vitamin D (target 100,000 IU/d for 5-212 days) produced hypercalcaemia in only 4/24 patients, [12] and patients with sarcoidosis and glucocorticoid-induced osteoporosis commonly take vitamin D supplements without developing hypercalcaemia. [13] Furthermore, countries at higher latitudes do not have consistently lower prevalence of hypercalcaemia than countries closer to the equator, [1] and prevalence of hypercalcaemia is similar in countries with and without dietary vitamin D fortification. [6] These findings suggest that vitamin D intake and production are not the sole causes of hypercalcaemia in sarcoidosis.

Despite the conflicting evidence over the role of vitamin D intake/production in sarcoidosis-associated hypercalcaemia, several authoritative reviews have recommended avoidance of sunlight exposure and vitamin D supplements. [6-8] Adopting such recommendations is likely to lead to vitamin D insufficiency, which is associated with a number of adverse skeletal outcomes including secondary hyperparathyroidism, increased bone turnover, low bone mineral density (BMD) and increased risk of fracture. [14] There is a high prevalence of low

1
2
3 BMD in cross-sectional studies of patients with sarcoidosis,[7 ,13 ,15-18] and glucocorticoid
4
5 use is common and well known to have adverse skeletal effects. Thus, it is possible that
6
7 treatment recommendations of sarcoidosis may worsen skeletal health by inadvertently
8
9 promoting vitamin D insufficiency.
10

11
12
13
14 There has been recent interest in the effects of vitamin D supplements in patients with
15
16 sarcoidosis.[19-22] We have carried out a randomized controlled trial to determine the effects
17
18 of vitamin D supplementation in patients with sarcoidosis and vitamin D insufficiency.
19
20

21 22 23 **Methods:**

24 25 Participants:

26
27 Patients with sarcoidosis attending the interstitial lung disease clinic at our hospital were invited
28
29 to participate. Newspaper advertisements were also placed. Potential participants were eligible if
30
31 they had sarcoidosis diagnosed by biopsy and/or typical pattern on high resolution computed
32
33 tomography and screening 25OHD <50 nmol/L, but were excluded if they had serum creatinine
34
35 >150 umol/L, nephrocalcinosis, albumin-adjusted serum calcium >2.55 mmol/L, concurrent
36
37 major systemic illness, or BMD T score <-2.5 at the spine or hip. Participants were recruited
38
39 between September 2007 and December 2010. The flow of participants is shown in Figure 1.
40
41
42
43
44

45 46 Protocol

47
48 Participants were randomized to receive either 50,000 IU of cholecalciferol or placebo weekly
49
50 for four weeks followed by 50,000 IU cholecalciferol or placebo every month for 11 months.
51
52 Patients were asked to continue their usual diet to maintain their dietary calcium intake in
53
54 accordance with locally recommended practice. Calcium supplements were not administered.
55
56 Treatment allocations were randomized by the study statistician, using a variable block size
57
58
59
60

1
2
3 schedule, based on computer-generated random numbers. Study medication was dispensed into
4
5 identical bottles and labelled with participant numbers by a staff member not otherwise involved
6
7 in the study. To ensure masking, only the statistician and this staff member had access to
8
9 treatment allocation, and neither had contact with participants. All other study personnel and
10
11 participants were blinded to treatment allocation throughout. The study received ethical
12
13 approval from the Northern X regional ethics committee and the trial was registered with the
14
15 Australian New Zealand Clinical Trials Registry, ACTRN12607000364471. All participants
16
17 gave written, informed consent.
18
19

20
21
22 The primary endpoint was the change in serum calcium over 12 months with vitamin D
23
24 supplementation. Secondary endpoints were the change in urine calcium, change in markers of
25
26 bone turnover, and change in BMD over 12 months. It was planned to recruit 40 participants, for
27
28 which the study had >80% power ($\alpha = 0.05$) to detect a difference in serum calcium of 0.10
29
30 mmol/L between groups. Recruitment was stopped after more than 3y when 27 participants were
31
32 recruited.
33
34
35

36 37 38 Measurements:

39
40 At baseline, every 2 weeks for 8 weeks, then at 12, 16, 26, 39, and 52 weeks, fasting blood
41
42 and second-voided morning urine samples were collected. Samples for calcitropic hormones
43
44 and bone turnover markers were stored at -70°C until they were batch-analyzed. At baseline,
45
46 4, 26, and 52 weeks, 24h urine samples were collected. The following assays were used: the
47
48 screening 25OHD was measured by radioimmunoassay (RIA) (DiaSorin, Stillwater, MN), but
49
50 all 25OHD samples from the study including the baseline sample were measured by liquid
51
52 chromatography- tandem mass spectrometry (LC-MS/MS) (ABSciex API 4000); 1,25OHD
53
54 by RIA (IDS, Tyne and Wear, UK), serum parathyroid hormone (PTH) by
55
56
57
58

1
2
3 electrochemiluminescence immunoassay (E170, Roche Diagnostics, Indianapolis, IN); serum
4
5 procollagen type-I N-terminal propeptide (PINP) and serum β -C-terminal telopeptide of type I
6
7 collagen (CTX) by the Roche Elecsys 2010 platform (Roche Diagnostics, Indianapolis, IN).

8
9
10 BMD was measured every 6 months at the lumbar spine, proximal femur and total body using a
11
12 GE Prodigy dual-energy x-ray absorptiometer (DXA) (GE Lunar, Madison WI). Daily calcium
13
14 intake was assessed at baseline using a validated questionnaire.[23]

15 16 17 18 Statistics:

19
20 Baseline differences between groups for continuous variables were assessed using Student's t-
21
22 test, and for categorical variables using the Chi-Square test. All analyses were carried out on an
23
24 intention-to-treat basis. A mixed models approach to repeated measures was used to examine the
25
26 time course of response in the treatment and control arms for serum calcium, urine calcium,
27
28 calcitropic hormones, bone turnover markers and BMD measurements by fitting main and
29
30 treatment-by-time interaction effects. Post-hoc comparisons between groups at individual time
31
32 points were explored using the method of Tukey. BMD data were analyzed using raw data,
33
34 although results are presented as percentage change from baseline adjusted for baseline between-
35
36 groups differences, for ease of interpretation. All tests were two-tailed and statistical significance
37
38 was set at $P < 0.05$. All statistical analyses were carried out using the SAS software package (SAS
39
40 Institute, Cary, NC version 9.2)

41 42 43 44 **Results:**

45
46
47 The baseline characteristics of the two groups were similar (Table 1).
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Baseline characteristics

	Vitamin D n=13	Placebo n=14	P
Age (y)	56 (10)	57 (9)	0.7
Female	10 (77)	9 (64)	0.7
Ethnicity			
European	10 (77)	9 (64)	0.7
Indian	1 (8)	3 (21)	
Other	1 (8)	2 (14)	
Weight (kg)	75 (19)	72 (13)	0.7
Dietary calcium intake (mg/d)	730 (670)	660 (33)	0.7
Smoking status			
Current	3 (23)	0 (0)	0.1
Never Smoked	8 (63)	9 (64)	>0.9
Glucorticoid use			
Past oral use	7 (54)	9 (64)	0.6
Current oral use	1 (8)	0 (0)	0.5
Current inhaled use	6 (46)	1 (7)	0.03
Sarcoidosis extent			
Pulmonary involvement	11 (85)	8 (57)	0.2
Extra-pulmonary involvement	6 (46)	7 (50)	0.8
Chest radiograph stage at baseline			0.3
Stage 0	1 (10)	6 (46)	
Stage 1	1 (10)	1 (8)	
Stage 2	1 (10)	0 (0)	
Stage 3	3 (30)	4 (31)	
Stage 4	4 (40)	2 (15)	
Bone density (g/cm ²)			
Lumbar spine	1.16 (0.19)	1.13 (0.11)	0.5
T score	-0.2 (1.6)	-0.6 (0.9)	0.5
Total hip	0.95 (0.11)	0.93 (0.11)	0.7
T score	-0.6 (0.9)	-0.8 (0.9)	0.8
Femoral neck	0.89 (0.13)	0.91 (0.09)	0.6
T score	-1.2 (1.0)	-0.9 (0.7)	0.5
Total body	1.15 (0.10)	1.11 (0.07)	0.2
Adjusted serum calcium (mmol/L)	2.24 (0.06)	2.26 (0.12)	0.6
Serum phosphate (mmol/L)	1.23 (0.15)	1.06 (0.17)	0.01
Serum creatinine (mmol/L)	74 (14)	77 (12)	0.5
24 hr urine calcium (mmol/d)	4.6 (3.4)	6.6 (5.2)	0.3

Screening 25 hydroxyvitamin D (nmol/) ^a	35 (12)	38 (9)	0.5
Baseline 25 hydroxyvitamin D (nmol/) ^a	40 (17)	45 (17)	0.4
1,25 dihydroxyvitamin D (pmol/L)	109 (34)	116 (25)	0.5
Parathyroid hormone (pmol/L)	4.0 (1.6)	4.9 (2.0)	0.2
P1NP (ug/L)	37 (12)	40 (15)	0.6
β-CTX (ng/L)	310 (130)	360 (210)	0.45

^a 25-hydroxyvitamin D were measured at the screening study visit using a Diasorin assay, while the baseline 25-hydroxyvitamin D at the first study visit (average 3 weeks later) were stored frozen until the end of the study and then measured with a liquid chromatography tandem mass spectrometry assay (see text). Data are mean (SD) or n (%). Abbreviations: P1NP- serum procollagen type-I N-terminal propeptide; β-CTX - serum β-C-terminal telopeptide of type I collagen.

The mean (range) 25OHD at the study screening visit was 35 (14-48) nmol/L in the treatment group, and 38 (12-49) nmol/L in the controls. The baseline 25OHD measurements from the first study visit (average 3 weeks after screening 25OHD) that were stored and then measured at the end of the study using a different assay were slightly higher than the screening 25OHD in both groups (Table 1). Vitamin D supplementation led to an immediate increase in 25OHD levels, and a sustained difference between the groups that persisted throughout the trial (P<0.001) (Figure 1). There was also an immediate increase in 1,25OHD levels in response to vitamin D supplementation, but this did not persist. While the between-groups differences over the trial were statistically significant (P=0.007), by the end of the trial 1,25OHD levels were similar in both groups (Figure 2).

1
2
3 Figure 3 shows that vitamin D supplements had no effect on either average albumin-adjusted
4 serum calcium ($P=0.46$) or 24h urine calcium levels ($P=0.10$) throughout the trial. There were no
5
6 between-group differences at any time point in participants with 24h urine calcium > 10
7
8 mmol/day (baseline vitamin D vs control- 1 vs. 4; 4 weeks- 4 vs. 4; 16 weeks 1 vs. 2; 52 weeks –
9
10 3 vs. 2). One participant in the vitamin D group and none in the control group had sustained
11
12 hypercalcaemia with 24h urine calcium > 10 mmol/day in all 3 visits during follow-up. One
13
14 participant developed hypercalcaemia during the trial- a 51y old female, diagnosed with
15
16 sarcoidosis 2y prior to study entry, with bilateral hilar lymphadenopathy, liver, and lung
17
18 involvement. She was taking inhaled glucocorticoids at study entry but no other medication. She
19
20 was assigned to vitamin D treatment and Table 2 shows that hypercalcaemia was recognized at 6
21
22 weeks, by which time she had taken five 50,000 IU doses of cholecalciferol. She was vitamin D
23
24 deficient at baseline, and treatment increased her 25OHD level to 69 nmol/L. There was a
25
26 marked increase in 1,25OHD, 24h urine calcium, serum phosphate, and creatinine levels and
27
28 suppression of PTH levels following vitamin D supplementation, but she remained
29
30 asymptomatic throughout. No further study medication was taken and the biochemical
31
32 abnormalities resolved without specific treatment by week 16 of the trial. When this participant
33
34 was excluded from the analyses for serum calcium and 24h urine calcium, the results did not
35
36 change substantially except there was no visible rise in the average albumin-adjusted serum
37
38 calcium at 6 and 8 weeks in the vitamin D group (data not shown).
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2: Time course of hypercalcaemia in patient randomized to vitamin D supplements

Week ^a	Dietary calcium (mg/d)	Serum calcium ^b (mmol/L)	Serum phosphate (mmol/L)	Serum creatinine (μmol/L)	24h urine calcium (mmol/d)	25OHD (nmol/L)	1,25OHD (pmol/L)	PTH (pmol/L)
0	460	2.26	1.24	76	4.2	18	77	2.3
2		2.36	1.28	74				
4		2.48	1.57	83	14.4	69	218	0.9
6		2.88	1.55	112				
7		2.87	1.31	125				
8		2.65	1.45	124				
12		2.46	1.23	93				
16		2.22	1.14	75				
26		2.28	1.04	71		31	81	2.2
52		2.27	1.11	78	6.7	41	77	2.1

^a study treatment was stopped at 6 weeks when hypercalcaemia was recognised. The last dose was taken at week 5, and five 50,000 IU doses of cholecalciferol were taken over 5 weeks.

^b albumin-adjusted serum calcium.

Abbreviations : 25OHD 25-hydroxyvitamin D, 1,25OHD 1,25-dihydroxyvitamin D, PTH-parathyroid hormone.

The effect of vitamin D supplements on bone turnover markers and PTH are shown in Figure 4 and on BMD in Figure 5. Vitamin D supplementation had no effect on any of these variables ($P > 0.16$ for all variables).

Other than the 1 participant treated with vitamin D who developed hypercalcaemia (proportion 8%, 95% confidence interval 1-33%), there were no other adverse events potentially related to

1
2
3 treatment during the trial. 1 participant (randomized to vitamin D) required prolonged treatment
4
5 with oral glucocorticoids, and 1 participant (randomized to placebo) received a single infusion of
6
7 zoledronic acid at 11 months, because of an underlying neurological disorder that had led to an
8
9 increased risk of falls and fracture.
10

11 12 13 14 **Discussion:**

15
16 Vitamin D supplementation of patients with sarcoidosis and vitamin D insufficiency did not alter
17
18 average serum calcium or urine calcium levels, but also did not affect BMD or markers of bone
19
20 turnover, and caused one case of significant hypercalcaemia. 25OHD levels were in a range
21
22 many experts consider sub-optimal at baseline (average <50 nmol/L) and vitamin D
23
24 supplementation led to average 25OHD levels of >75nmol/L throughout the trial, levels
25
26 generally considered to indicate adequate vitamin D status. Thus, our findings of an absence of
27
28 benefit from vitamin D supplements, together with infrequent but significant hypercalcaemia,
29
30 suggest that there is little indication for vitamin D supplements in patients with sarcoidosis and
31
32 vitamin D insufficiency.
33
34
35
36
37

38
39 Recent research has linked low 25OHD levels with numerous adverse non-skeletal
40
41 outcomes.[24] This information, when added to the existing data linking low 25OHD levels with
42
43 adverse skeletal outcomes,[14] has lead to renewed interest in the role of vitamin D in health. In
44
45 clinical practice, there has been a large increase in measurement of 25OHD [25 ,26] and calls for
46
47 widespread vitamin D supplementation.[27] However, these associations between low vitamin D
48
49 status and adverse health outcomes have been generated from observational studies which
50
51 cannot determine causality. There are now a growing number of randomized controlled trials
52
53 that have not shown benefits from vitamin D supplements on a wide range of endpoints. Thus,
54
55 meta-analyses of such trials have shown no benefit of vitamin D supplementation (when used
56
57
58
59
60

1
2
3 without co-administered calcium supplements) on falls,[28] fractures,[29] mortality,[30]
4
5 cardiovascular events,[30] and cancer.[31] In our study, which was powered to assess serum
6
7 calcium rather than BMD effects, we did not find evidence for benefit of vitamin D supplements
8
9 on surrogate markers of skeletal health in a group of patients with sarcoidosis who had mildly
10
11 low 25OHD levels, consistent with these findings.
12
13

14
15
16 The mechanism of hypercalcaemia in sarcoidosis is well described. Extra-renal production of
17
18 1,25OHD in activated macrophages in granulomata leads to increased intestinal calcium
19
20 absorption and increased bone resorption which collectively produce hypercalcaemia.[3] It is
21
22 unclear whether circulating 25OHD levels are implicated in causing hypercalcaemia, with some
23
24 evidence supporting [4-10] and some not supporting [1 ,6 ,11-13] each viewpoint, as discussed
25
26 earlier. Our study tends to support the former view for two reasons: firstly, one patient developed
27
28 significant hypercalcaemia within a short time of starting vitamin D supplements, and there was
29
30 prompt resolution of the hypercalcaemia without other treatment after the supplements were
31
32 stopped. Secondly, in the entire cohort there was a rapid increase in 1,25OHD with vitamin D
33
34 supplements, although the increase did not persist. Both pieces of data suggest that abrupt
35
36 changes in 25OHD can increase 1,25OHD, and in a minority of patients this can cause
37
38 hypercalcaemia. The characteristics that predispose to the development of hypercalcaemia
39
40 remain unclear. It is possible that increasing 25OHD more slowly using small, incrementally
41
42 increasing doses of vitamin D, may avoid this complication, but this would need to be tested in
43
44 closely monitored clinical trials.
45
46
47
48
49
50

51
52 Our study has several limitations. It is a small study, but based on the data from the placebo
53
54 group, the study had 80% power to detect a difference between the groups of 0.1 mmol/L in the
55
56 primary endpoint- serum calcium. Similarly, the detectable differences for other variables were
57
58

1
2
3 BMD 2.2%-2.7% depending on site, PTH 1.5 pmol/L, P1NP 5.6 µg/L, and CTX 220 ng/L.
4
5 Differences below these amounts would be of questionable clinical relevance. Thus, while small,
6
7 the study did have power to detect clinically relevant differences. A second limitation is
8
9 regarding the screening vitamin D measurement. All participants had 25OHD <50 nmol/L at the
10
11 screening visit measured using a Diasorin RIA. All study samples for 25OHD were frozen and
12
13 then assayed in a single batch at another laboratory using an LC-MS/MS assay. The 25OHD
14
15 levels measured using LC-MS/MS were on average slightly higher than those measured using
16
17 the Diasorin immunoassay, and 9/27 participants had 25OHD > 50 nmol/L at the baseline visit.
18
19 Variation between results from different 25OHD assays is well-described, and while LC-MS/MS
20
21 is usually considered the gold standard, both immunoassays and LC-MS/MS have
22
23 limitations.[32] Few participants had 25OHD < 25 nmol at baseline, thus our results may not
24
25 apply to individuals with very low 25OHD levels.
26
27
28
29
30
31

32 In summary, we did not find evidence of benefits on surrogate markers of skeletal health from
33
34 vitamin D supplementation in patients with sarcoidosis and vitamin D insufficiency. However,
35
36 there was evidence of harm with one case of significant hypercalcaemia. The absence of benefit
37
38 together with the risk of infrequent but significant adverse effects suggests that there is little
39
40 indication for vitamin D supplements in patients with sarcoidosis and vitamin D levels in the
41
42 range in this study (12 – 49 nmol/L).
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Funding:

This study was funded by the Health Research Council of New Zealand, and the Greenlane Research and Education Fund. The sponsors of the study had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Disclosure: All the authors state that they have no conflicts of interest.

Contributorship:

MB, AG, AH, IR, and MW designed the study. SF and AH ran the study. MB and GG carried out the statistical analyses. MB drafted the article. All authors critically reviewed the draft manuscript and approved the final version. MB is the guarantor of the article.

Data sharing:

There are no additional data available.

References

1. James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. *Ann N Y Acad Sci* 1976;**278**:321-34.
2. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Jr., Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. *Am J Respir Crit Care Med* 2001;**164**:1885-9.
3. Singer FR, Adams JS. Abnormal calcium homeostasis in sarcoidosis. *N Engl J Med* 1986;**315**:755-7.
4. Bell NH, Gill JR, Jr., Bartter FC. On the Abnormal Calcium Absorption in Sarcoidosis. Evidence for Increased Sensitivity to Vitamin D. *Am J Med* 1964;**36**:500-13.
5. Sandler LM, Winearls CG, Fraher LJ, Clemens TL, Smith R, O'Riordan JL. Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3. *Q J Med* 1984;**53**:165-80.
6. Sharma OP. Vitamin D, calcium, and sarcoidosis. *Chest* 1996;**109**:535-9.
7. Rizzato G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. *Thorax* 1998;**53**:425-9.
8. Conron M, Young C, Beynon HL. Calcium metabolism in sarcoidosis and its clinical implications. *Rheumatology (Oxford)* 2000;**39**:707-13.
9. Bonnema SJ, Moller J, Marving J, Kvetny J. Sarcoidosis causes abnormal seasonal variation in 1,25-dihydroxy-cholecalciferol. *J Intern Med* 1996;**239**:393-8.
10. Taylor RL, Lynch HJ, Jr., Wysor WG, Jr. Seasonal influence of sunlight on the hypercalcemia of sarcoidosis. *Am J Med* 1963;**34**:221-7.
11. Alberts C, van den Berg H. Calcium metabolism in sarcoidosis. A follow-up study with respect to parathyroid hormone and vitamin D metabolites. *Eur J Respir Dis* 1986;**68**:186-94.
12. Larsson LG, Liljestrang A, Wahlund H. Treatment of sarcoidosis with calciferol. *Acta Med Scand* 1952;**143**:281-87.
13. Adler RA, Funkhouser HL, Petkov VI, Berger MM. Glucocorticoid-induced osteoporosis in patients with sarcoidosis. *Am J Med Sci* 2003;**325**:1-6.
14. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. *Endocr Rev* 2001;**22**:477-501.

15. Montemurro L, Fraioli P, Rizzato G. Bone loss in untreated longstanding sarcoidosis. *Sarcoidosis* 1991;**8**:29-34.
16. Rottoli P, Gonnelli S, Silitro S, Zacchei F, Fabbrini D, Gennari C, et al. Alterations in calcium metabolism and bone mineral density in relation to the activity of sarcoidosis. *Sarcoidosis* 1993;**10**:161-2.
17. Hamada K, Nagai S, Tsutsumi T, Izumi T. Bone mineral density and vitamin D in patients with sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 1999;**16**:219-23.
18. Sipahi S, Tuzun S, Ozaras R, Calis HT, Ozaras N, Tuzun F, et al. Bone mineral density in women with sarcoidosis. *J Bone Miner Metab* 2004;**22**:48-52.
19. Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. *Semin Respir Crit Care Med* 2010;**31**:474-84.
20. Sharma OP. Vitamin D and sarcoidosis. *Curr Opin Pulm Med* 2010;**16**:487-8.
21. Sage RJ, Rao DS, Burke RR, Lim HW. Preventing vitamin D toxicity in patients with sarcoidosis. *J Am Acad Dermatol* 2011;**64**:795-6.
22. Sweiss NJ, Lower EE, Korsten P, Niewold TB, Favus MJ, Baughman RP. Bone health issues in sarcoidosis. *Curr Rheumatol Rep* 2011;**13**:265-72.
23. Angus RM, Sambrook PN, Pocock NA, Eisman JA. A simple method for assessing calcium intake in Caucasian women. *J Am Diet Assoc* 1989;**89**:209-14.
24. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;**357**:266-81.
25. Sattar N, Welsh P, Panarelli M, Forouhi NG. Increasing requests for vitamin D measurement: costly, confusing, and without credibility. *Lancet* 2012;**379**:95-6.
26. Bolland MJ, Grey A, Davidson JS, Cundy T, Reid IR. Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand? *N Z Med J* 2012;**125**:83-91.
27. Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. *BMJ* 2010;**340**:b5664.
28. Murad MH, Elamin KB, Abu Elnour NO, Elamin MB, Alkatib AA, Fatourehchi MM, et al. Clinical review: The effect of vitamin D on falls: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2011;**96**:2997-3006.
29. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. *Cochrane Database Syst Rev* 2009:CD000227.

- 1
2
3 30. Elamin MB, Abu Elnour NO, Elamin KB, Fatourehchi MM, Alkatib AA, Almandoz
4 JP, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-
5 analysis. *J Clin Endocrinol Metab* 2011;**96**:1931-42.
6
7
8 31. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D With or Without
9 Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-
10 analysis for the U.S. Preventive Services Task Force. *Ann Intern Med* 2011;**155**:827-
11 38.
12
13 32. Carter GD. 25-Hydroxyvitamin D assays: the quest for accuracy. *Clin Chem*
14 2009;**55**:1300-2.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Figure 1: flow of participants
4
5
6
7


8 Figure 2: The effect of vitamin D supplementation on 25-hydroxyvitamin D and 1,25-
9 dihydroxyvitamin D levels. Data are mean and 95% confidence interval. P values are for
10 time-by-treatment interaction. Asterisks indicate significant between-groups differences at
11 individual points.
12
13
14
15
16
17

18 Figure 3: The effect of vitamin D supplementation on albumin-adjusted serum calcium and
19 24h urine calcium levels. Data are mean and 95% confidence interval. P values are for time-
20 by-treatment interaction.
21
22
23
24
25
26
27

28 Figure 4: The effect of vitamin D supplementation on bone turnover markers and serum
29 parathyroid (PTH). Data are mean and 95% confidence interval. P values are for time-by-
30 treatment interaction. Abbreviations: Procollagen type-I N-terminal propeptide: P1NP; β -C-
31 terminal telopeptide of type I collagen: β -CTx
32
33
34
35
36
37
38

39 Figure 5: The effect of vitamin D supplementation on bone mineral density (BMD). Data are
40 mean and 95% confidence interval for the percentage change from baseline adjusted for
41 baseline BMD. P values are for time-by-treatment interaction.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Redundant version of Figure
116x95mm (600 x 600 DPI)




Figure 2: The effect of vitamin D supplementation on 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels. Data are mean and 95% confidence interval. P values are for time-by-treatment interaction. Asterisks indicate significant between-groups differences at individual points.
172x296mm (600 x 600 DPI)




Figure 3: The effect of vitamin D supplementation on albumin-adjusted serum calcium and 24h urine calcium levels. Data are mean and 95% confidence interval. P values are for time-by-treatment interaction. 139x175mm (600 x 600 DPI)




Figure 4: The effect of vitamin D supplementation on bone turnover markers and serum parathyroid (PTH). Data are mean and 95% confidence interval. P values are for time-by-treatment interaction. Abbreviations: Procollagen type-I N-terminal propeptide: P1NP; β -C-terminal telopeptide of type I collagen: β -CTX
176x314mm (600 x 600 DPI)




Figure 5: The effect of vitamin D supplementation on bone mineral density (BMD). Data are mean and 95% confidence interval for the percentage change from baseline adjusted for baseline BMD. P values are for time-by-treatment interaction.
86x62mm (600 x 600 DPI)



Randomized controlled trial of vitamin D supplementation in sarcoidosis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003562.R1
Article Type:	Research
Date Submitted by the Author:	22-Aug-2013
Complete List of Authors:	Bolland, Mark; University of Auckland, Department of Medicine Wilsher, Margaret; Auckland District Health Board, Respiratory Services Grey, Andrew; University of Auckland, Department of Medicine Horne, Anne; University of Auckland, Department of Medicine Fenwick, Sheryl; University of Auckland, Department of Medicine Gamble, Greg; University of Auckland, Department of Medicine Reid, Ian; University of Auckland, Department of Medicine
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	THORACIC MEDICINE, Clinical trials < THERAPEUTICS, Calcium & bone < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

Title: Randomized controlled trial of vitamin D supplementation in sarcoidosis.

Running title: Vitamin D supplementation and sarcoidosis

Authors:

Mark J Bolland, MBChB, PhD,¹
Margaret L Wilsher, MD,^{1,2}
Andrew Grey, MD,¹
Anne M Horne, MBChB,¹
Sheryl Fenwick, BAppSc¹
Greg D Gamble, MSc¹
Ian R Reid, MD,¹

Affiliation:

¹Department of Medicine, University of Auckland, Private Bag 92 019, Auckland 1142, New Zealand; ² Green Lane Respiratory Services, Auckland District Health Board, Private Bag 92024, Auckland 1142, New Zealand

Address for correspondence/reprints:

Mark Bolland
Bone and Joint Research Group,
Department of Medicine, University of Auckland
Private Bag 92 019, Auckland 1142, New Zealand
Email: m.bolland@auckland.ac.nz
Ph 64 9 373 7999
Fax 64 9 373 7677

Funding:

This study was funded by the Health Research Council of New Zealand, and the Greenlane Research and Education Fund.

Word counts:

Text only: 2433
Abstract: 275
Figures: 5
Tables: 2

Disclosure: All the authors state that they have no conflicts of interest.

Key words: vitamin D, hypercalcaemia, sarcoidosis, bone turnover, bone mineral density

Trial registration: This trial is registered at the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au). The registration number is ACTRN12607000364471, date of registration 5/7/2007.

Article focus:

- The effect of vitamin D supplementation on calcium homeostasis and skeletal health in sarcoidosis
- A randomized, placebo-controlled trial of vitamin D supplements in 27 normocalcaemic patients with sarcoidosis and 25-hydroxyvitamin D <50nmol/L

Key messages:

- Vitamin D supplementation had no effect on serum or urine calcium, bone turnover markers or bone mineral density over 12 months, but caused 1 case of significant hypercalcaemia.
- This clinical trial suggests that vitamin D supplements are not beneficial and may be harmful for patients with sarcoidosis and mildly low vitamin D levels.

Limitations:

- The study had limited power to detect small differences in bone density and bone turnover markers.
- Few participants had 25-hydroxyvitamin D levels < 25 nmol/L, and therefore the findings may not apply to individuals with very low vitamin D levels.

Abstract**Objectives:**

The role vitamin D intake/production plays in sarcoidosis-associated hypercalcaemia is uncertain. However, authoritative reviews have recommended avoiding sunlight exposure and vitamin D supplements, which might lead to adverse skeletal outcomes from vitamin D insufficiency. We investigated the effects of vitamin D supplementation on surrogate measures of skeletal health in patients with sarcoidosis and vitamin D insufficiency.

Design:

Randomized, placebo-controlled trial

Setting: Clinical research centre

Participants: 27 normocalcaemic patients with sarcoidosis and 25-hydroxyvitamin D (25OHD) <50nmol/L.

Intervention: 50,000IU weekly cholecalciferol for 4 weeks, then 50,000IU monthly for 11 months) or placebo

Primary and secondary outcome measures: The primary endpoint was the change in serum calcium over 12 months, and secondary endpoints included measurements of calcitropic hormones, bone turnover markers, and bone mineral density (BMD).

Results

1
2
3 The mean age of participants was 57y and 70% were female. The mean (SD) screening
4
5 25OHD was 35(12) and 38(9) nmol/L in the treatment and control groups, respectively.
6
7 Vitamin D supplementation increased 25OHD to 94 nmol/L after 4 weeks, 84 nmol/L at 6
8
9 months, and 78 nmol/L at 12 months, while levels remained stable in the control group. 1,25
10
11 dihydroxyvitamin D levels were significantly different between the groups at 4 weeks, but not
12
13 at 6 or 12 months. There were no between-groups differences in albumin-adjusted serum
14
15 calcium, 24h urine calcium, markers of bone turnover, parathyroid hormone, or BMD over
16
17 the trial. One participant developed significant hypercalcaemia after 6 weeks (total
18
19 cholecalciferol dose 250,000IU).
20
21
22
23
24

25 **Conclusions**

26
27 In patients with sarcoidosis and 25OHD <50nmol/L, vitamin D supplements did not alter
28
29 average serum calcium or urine calcium, but had no benefit on surrogate markers of skeletal
30
31 health and caused one case of significant hypercalcaemia.
32
33
34
35

36 **Trial registration:** This trial is registered at the Australian New Zealand Clinical Trials
37
38 Registry (www.anzctr.org.au). The registration number is ACTRN12607000364471, date of
39
40 registration 5/7/2007.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction:

Hypercalcaemia occurs commonly in sarcoidosis, with an estimated prevalence of 4-11%. [1,2] Hypercalcaemia results from dysregulated production of 1,25-dihydroxyvitamin D (1,25OHD) by activated macrophages in granulomata. [3] Although the mechanism of hypercalcaemia is known, the role of vitamin D intake and production is less certain. On one hand, cases of hypercalcaemia and sarcoidosis precipitated by sunlight exposure or vitamin D supplements have been reported, [4-8] and there is seasonal variation in 1,25OHD levels [9] and the prevalence of hypercalcaemia. [7, 9, 10] These findings suggest that increases in 25-hydroxyvitamin D (25OHD) levels through sunlight exposure or vitamin D intake contribute to the hypercalcaemia. On the other hand, studies have reported no correlation between 25OHD, 1,25OHD, and serum calcium, [11] historical studies of treatment with very large doses of vitamin D (target 100,000 IU/d for 5-212 days) produced hypercalcaemia in only 4/24 patients, [12] and patients with sarcoidosis and glucocorticoid-induced osteoporosis commonly take vitamin D supplements without developing hypercalcaemia. [13] Furthermore, countries at higher latitudes do not have consistently lower prevalence of hypercalcaemia in sarcoidosis than countries closer to the equator, [1] and prevalence of hypercalcaemia in sarcoidosis is similar in countries with and without dietary vitamin D fortification. [6] These findings suggest that vitamin D intake and production are not the sole causes of hypercalcaemia in sarcoidosis.

Despite the conflicting evidence over the role of vitamin D intake/production in sarcoidosis-associated hypercalcaemia, several authoritative reviews have recommended avoidance of sunlight exposure and vitamin D supplements. [6-8] Adopting such recommendations is likely to lead to vitamin D insufficiency, which is associated with a number of adverse skeletal outcomes including secondary hyperparathyroidism, increased bone turnover, low bone

1
2
3 mineral density (BMD) and increased risk of fracture.[14] There is a high prevalence of low
4
5 BMD in cross-sectional studies of patients with sarcoidosis,[7 ,13 ,15-18] and glucocorticoid
6
7 use is common and well known to have adverse skeletal effects. Thus, it is possible that
8
9 treatment recommendations of sarcoidosis may worsen skeletal health by inadvertently
10
11 promoting vitamin D insufficiency.
12
13

14
15
16 There has been recent interest in the effects of vitamin D supplements in patients with
17
18 sarcoidosis.[19-22] We have carried out a randomized controlled trial to determine the effects
19
20 of vitamin D supplementation on surrogate measures of skeletal health in patients with
21
22 sarcoidosis and vitamin D insufficiency.
23
24

25 26 27 **Methods:**

28 29 Participants:

30
31 Patients with sarcoidosis attending the interstitial lung disease clinic at our hospital were invited
32
33 to participate. Newspaper advertisements were also placed. Potential participants were eligible if
34
35 they had sarcoidosis diagnosed by biopsy and/or typical pattern on high resolution computed
36
37 tomography and screening 25OHD <50 nmol/L, but were excluded if they had serum creatinine
38
39 >150 umol/L, nephrocalcinosis, albumin-adjusted serum calcium >2.55 mmol/L, concurrent
40
41 major systemic illness, or BMD T score <-2.5 at the spine or hip. Participants were recruited
42
43 between September 2007 and December 2010. The flow of participants is shown in Figure 1.
44
45
46
47
48

49 50 Protocol

51
52 Participants were randomized to receive either 50,000 IU of cholecalciferol or placebo weekly
53
54 for four weeks followed by 50,000 IU cholecalciferol or placebo every month for 11 months.
55

56 Patients were asked to continue their usual diet to maintain their dietary calcium intake in
57

1
2
3 accordance with locally recommended practice. Calcium supplements were not administered.
4
5 Treatment allocations were randomized by the study statistician, using a variable block size
6
7 schedule, based on computer-generated random numbers. Study medication was dispensed into
8
9 identical bottles and labelled with participant numbers by a staff member not otherwise involved
10
11 in the study. To ensure masking, only the statistician and this staff member had access to
12
13 treatment allocation, and neither had contact with participants. All other study personnel and
14
15 participants were blinded to treatment allocation throughout. The study received ethical
16
17 approval from the Northern X regional ethics committee and the trial was registered with the
18
19 Australian New Zealand Clinical Trials Registry, ACTRN12607000364471. All participants
20
21 gave written, informed consent.
22
23
24
25
26

27 The primary endpoint was the change in serum calcium over 12 months with vitamin D
28
29 supplementation. Secondary endpoints were the change in urine calcium, change in markers of
30
31 bone turnover, and change in BMD over 12 months. It was planned to recruit 40 participants, for
32
33 which the study had >80% power ($\alpha = 0.05$) to detect a difference in serum calcium of 0.10
34
35 mmol/L between groups. Recruitment was stopped after more than 3y when 27 participants were
36
37 recruited.
38
39
40
41
42

43 Measurements:

44
45 At baseline, every 2 weeks for 8 weeks, then at 12, 16, 26, 39, and 52 weeks, fasting blood
46
47 and second-voided morning urine samples were collected. Samples for calcitropic hormones
48
49 and bone turnover markers were stored at -70°C until they were batch-analyzed. At baseline,
50
51 4, 26, and 52 weeks, 24h urine samples were collected. The following assays were used: the
52
53 screening 25OHD was measured by radioimmunoassay (RIA) (DiaSorin, Stillwater, MN), but
54
55 all 25OHD samples from the study including the baseline sample were measured by liquid
56
57
58
59
60

1
2
3 chromatography- tandem mass spectrometry (LC-MS/MS) (ABSciex API 4000); 1,25OHD
4
5 by RIA (IDS, Tyne and Wear, UK), serum parathyroid hormone (PTH) by
6
7 electrochemiluminescence immunoassay (E170, Roche Diagnostics, Indianapolis, IN); serum
8
9 procollagen type-I N-terminal propeptide (P1NP) and serum β -C-terminal telopeptide of type I
10
11 collagen (CTX) by the Roche Elecsys 2010 platform (Roche Diagnostics, Indianapolis, IN).
12
13
14 BMD was measured every 6 months at the lumbar spine, proximal femur and total body using a
15
16 GE Prodigy dual-energy x-ray absorptiometer (DXA) (GE Lunar, Madison WI). Daily calcium
17
18 intake was assessed at baseline using a validated questionnaire.[23]
19
20

21 22 23 Statistics:

24
25 Baseline differences between groups for continuous variables were assessed using Student's t-
26
27 test, and for categorical variables using the Chi-Square test. All analyses were carried out on an
28
29 intention-to-treat basis. A mixed models approach to repeated measures with an unstructured
30
31 covariance structure was used to examine the time course of response in the treatment and
32
33 control arms for serum calcium, urine calcium, calcitropic hormones, bone turnover markers and
34
35 BMD measurements by fitting main and treatment-by-time interaction effects. Post-hoc
36
37 comparisons between groups at individual time points were explored using the method of Tukey.
38
39 BMD data were analyzed using raw data, although results are presented as percentage change
40
41 from baseline adjusted for baseline between-groups differences, for ease of interpretation. All
42
43 tests were two-tailed and hypothesis tests were deemed significant for $P < 0.05$. All statistical
44
45 analyses were carried out using the SAS software package (SAS Institute, Cary, NC version 9.2)
46
47
48
49
50

51 52 **Results:**

53
54 The baseline characteristics of the two groups were similar (Table 1). The mean (range) 25OHD
55
56 at the study screening visit was 35 (14-48) nmol/L in the treatment group, and 38 (12-49)
57
58
59
60

1
2
3 nmol/L in the controls. The baseline 25OHD measurements from the first study visit (average 3
4 weeks after screening 25OHD) that were stored and then measured at the end of the study using
5 a different assay were slightly higher than the screening 25OHD in both groups (Table 1).
6
7

8
9 Vitamin D supplementation led to an immediate increase in 25OHD levels, and a sustained
10 difference between the groups that persisted throughout the trial ($P<0.001$) (Figure 2). There was
11 also an immediate increase in 1,25OHD levels in response to vitamin D supplementation, but
12 this did not persist. While the between-groups differences over the trial were statistically
13 significant ($P=0.007$), by the end of the trial 1,25OHD levels were similar in both groups (Figure
14 2).
15
16
17
18
19
20
21
22
23
24

25 Figure 3 shows that vitamin D supplements had no effect on either average albumin-adjusted
26 serum calcium ($P=0.46$) or 24h urine calcium levels ($P=0.10$) throughout the trial. There were no
27 between-group differences at any time point in participants with 24h urine calcium > 10
28 mmol/day (baseline vitamin D vs control- 1 vs. 4; 4 weeks- 4 vs. 4; 16 weeks 1 vs. 2; 52 weeks –
29 3 vs. 2). One participant in the vitamin D group and none in the control group had sustained
30 hypercalcaemia with 24h urine calcium > 10 mmol/day in all 3 visits during follow-up. One
31 participant developed hypercalcaemia during the trial- a 51y old female, diagnosed with
32 sarcoidosis 2y prior to study entry, with bilateral hilar lymphadenopathy, liver, and lung
33 involvement. She was taking inhaled glucocorticoids at study entry but no other medication. She
34 was assigned to vitamin D treatment and Table 2 shows that hypercalcaemia was recognized at 6
35 weeks, by which time she had taken five 50,000 IU doses of cholecalciferol. She was vitamin D
36 deficient at baseline, and treatment increased her 25OHD level to 69 nmol/L. There was a
37 marked increase in 1,25OHD, 24h urine calcium, serum phosphate, and creatinine levels and
38 suppression of PTH levels following vitamin D supplementation, but she remained
39 asymptomatic throughout. No further study medication was taken and the biochemical
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 abnormalities resolved without specific treatment by week 16 of the trial. When this participant
4
5 was excluded from the analyses for serum calcium and 24h urine calcium, the results did not
6
7 change substantially except there was no visible rise in the average albumin-adjusted serum
8
9 calcium at 6 and 8 weeks in the vitamin D group (data not shown).
10

11
12
13
14 The effect of vitamin D supplements on bone turnover markers and PTH are shown in Figure 4
15
16 and on BMD in Figure 5. Vitamin D supplementation had no effect on any of these variables
17
18 ($P>0.16$ for all variables).
19

20
21
22
23 Other than the 1 participant treated with vitamin D who developed hypercalcaemia (proportion
24
25 8%, 95% confidence interval 1-33%), there were no other adverse events potentially related to
26
27 treatment during the trial. 1 participant (randomized to vitamin D) required prolonged treatment
28
29 with oral glucocorticoids, and 1 participant (randomized to placebo) received a single infusion of
30
31 zoledronic acid at 11 months, because of an underlying neurological disorder that had led to an
32
33 increased risk of falls and fracture.
34
35
36
37

38 **Discussion:**

39
40 Vitamin D supplementation of patients with sarcoidosis and vitamin D insufficiency did not alter
41
42 average serum calcium or urine calcium levels, but also did not affect BMD or markers of bone
43
44 turnover, and caused one case of significant hypercalcaemia. 25OHD levels were in a range
45
46 many experts consider sub-optimal at baseline (average <50 nmol/L) and vitamin D
47
48 supplementation led to average 25OHD levels of >75 nmol/L throughout the trial, levels
49
50 generally considered to indicate adequate vitamin D status. Thus, our findings of an absence of
51
52 benefit from vitamin D supplements, together with infrequent but significant hypercalcaemia,
53
54
55
56
57
58
59
60

1
2
3 suggest that there is little indication for vitamin D supplements in patients with sarcoidosis and
4
5 vitamin D insufficiency.
6
7

8
9
10 Recent research has linked low 25OHD levels with numerous adverse non-skeletal
11
12 outcomes.[24] This information, when added to the existing data linking low 25OHD levels with
13
14 adverse skeletal outcomes,[14] has lead to renewed interest in the role of vitamin D in health. In
15
16 clinical practice, there has been a large increase in measurement of 25OHD[25 ,26] and calls for
17
18 widespread vitamin D supplementation.[27] However, these associations between low vitamin D
19
20 status and adverse health outcomes have been generated from observational studies which
21
22 cannot determine causality. There are now a growing number of randomized controlled trials
23
24 that have not shown benefits from vitamin D supplements on a wide range of endpoints. Thus,
25
26 meta-analyses of such trials have shown no benefit of vitamin D supplementation (when used
27
28 without co-administered calcium supplements) on falls,[28] fractures,[29] mortality,[30]
29
30 cardiovascular events,[30] and cancer.[31] In our study, which was powered to assess serum
31
32 calcium rather than BMD effects, we did not find evidence for benefit of vitamin D supplements
33
34 on surrogate markers of skeletal health in a group of patients with sarcoidosis who had mildly
35
36 low 25OHD levels, consistent with these findings.
37
38
39
40
41
42

43 The mechanism of hypercalcaemia in sarcoidosis is well described. Extra-renal production of
44
45 1,25OHD in activated macrophages in granulomata leads to increased intestinal calcium
46
47 absorption and increased bone resorption which collectively produce hypercalcaemia.[3] It is
48
49 unclear whether circulating 25OHD levels are implicated in causing hypercalcaemia, with some
50
51 evidence supporting [4-10] and some not supporting [1 ,6 ,11-13] each viewpoint, as discussed
52
53 earlier. Our study tends to support the former view for two reasons: firstly, one patient developed
54
55 significant hypercalcaemia within a short time of starting vitamin D supplements, and there was
56
57
58
59
60

1
2
3 prompt resolution of the hypercalcaemia without other treatment after the supplements were
4 stopped. Secondly, in the entire cohort there was a rapid increase in 1,25OHD with vitamin D
5 supplements, although the increase did not persist. Both pieces of data suggest that abrupt
6 changes in 25OHD can increase 1,25OHD, and in a minority of patients this can cause
7 hypercalcaemia. The characteristics that predispose to the development of hypercalcaemia
8 remain unclear. It is possible that increasing 25OHD more slowly using small, incrementally
9 increasing doses of vitamin D, may avoid this complication, but this would need to be tested in
10 closely monitored clinical trials.
11
12
13
14
15
16
17
18
19

20
21
22 Our study has several limitations. It is a small study and therefore may be at risk of Type II error.
23 We carried out simulations to explore what effect sizes could have been statistically significant
24 in this study. We simulated an increased effect size in the treatment group (without varying data
25 in the placebo group or the sample size) in the models used in the study analyses. A difference
26 between the groups at 1y of 0.06 mmol/L in serum calcium, the primary endpoint, would have
27 reached conventional statistical significance. This is 60% of the value used in the study power
28 calculation (0.1 mmol/L) that we considered to be clinically relevant when designing the study.
29 Similarly, the corresponding between-groups differences that would have reached statistical
30 significance for the other main endpoints were: 2.4 pmol/L for PTH, 7 µg/L for P1NP, 140 ng/L
31 for CTX, and 0.5% - 1.9% for BMD, depending on site. Differences below these amounts would
32 be of questionable clinical relevance. Thus, while small, the study did have more than adequate
33 power to detect clinically relevant differences. A second limitation is regarding the screening
34 vitamin D measurement. All participants had 25OHD <50 nmol/L at the screening visit
35 measured using a Diasorin RIA. All study samples for 25OHD were frozen and then assayed in
36 a single batch at another laboratory using an LC-MS/MS assay. The 25OHD levels measured
37 using LC-MS/MS were on average slightly higher than those measured using the Diasorin
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 immunoassay, and 9/27 participants had 25OHD > 50 nmol/L at the baseline visit. Variation
4
5 between results from different 25OHD assays is well-described, and while LC-MS/MS is
6
7 usually considered the gold standard, both immunoassays and LC-MS/MS have limitations.[32]
8
9 Few participants had 25OHD < 25 nmol at baseline, thus our results may not apply to
10
11 individuals with very low 25OHD levels.
12
13

14
15
16 In summary, we did not find evidence of benefits on surrogate markers of skeletal health from
17
18 vitamin D supplementation in patients with sarcoidosis and vitamin D insufficiency. However,
19
20 there was evidence of harm with one case of significant hypercalcaemia. The absence of benefit
21
22 together with the risk of infrequent but significant adverse effects suggests that there is little
23
24 indication for vitamin D supplements in patients with sarcoidosis and vitamin D levels in the
25
26 range in this study (12 – 49 nmol/L).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Funding:

This study was funded by the Health Research Council of New Zealand, and the Greenlane Research and Education Fund. The sponsors of the study had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Disclosure: All the authors state that they have no conflicts of interest.

Contributorship:

MB, AG, AH, IR, and MW designed the study. SF and AH ran the study. MB and GG carried out the statistical analyses. MB drafted the article. All authors critically reviewed the draft manuscript and approved the final version. MB is the guarantor of the article.

Data sharing:

There are no additional data available.

References

1. James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. *Ann N Y Acad Sci* 1976;**278**:321-34.
2. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Jr., Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. *Am J Respir Crit Care Med* 2001;**164**:1885-9.
3. Singer FR, Adams JS. Abnormal calcium homeostasis in sarcoidosis. *N Engl J Med* 1986;**315**:755-7.
4. Bell NH, Gill JR, Jr., Bartter FC. On the Abnormal Calcium Absorption in Sarcoidosis. Evidence for Increased Sensitivity to Vitamin D. *Am J Med* 1964;**36**:500-13.
5. Sandler LM, Winearls CG, Fraher LJ, Clemens TL, Smith R, O'Riordan JL. Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3. *Q J Med* 1984;**53**:165-80.
6. Sharma OP. Vitamin D, calcium, and sarcoidosis. *Chest* 1996;**109**:535-9.
7. Rizzato G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. *Thorax* 1998;**53**:425-9.
8. Conron M, Young C, Beynon HL. Calcium metabolism in sarcoidosis and its clinical implications. *Rheumatology (Oxford)* 2000;**39**:707-13.
9. Bonnema SJ, Moller J, Marving J, Kvetny J. Sarcoidosis causes abnormal seasonal variation in 1,25-dihydroxy-cholecalciferol. *J Intern Med* 1996;**239**:393-8.
10. Taylor RL, Lynch HJ, Jr., Wysor WG, Jr. Seasonal influence of sunlight on the hypercalcemia of sarcoidosis. *Am J Med* 1963;**34**:221-7.

- 1
2
3 11. Alberts C, van den Berg H. Calcium metabolism in sarcoidosis. A follow-up study
4 with respect to parathyroid hormone and vitamin D metabolites. *Eur J Respir Dis*
5 1986;**68**:186-94.
6
7
- 8
9 12. Larsson LG, Liljestrand A, Wahlund H. Treatment of sarcoidosis with calciferol. *Acta*
10 *Med Scand* 1952;**143**:281-87.
11
- 12 13. Adler RA, Funkhouser HL, Petkov VI, Berger MM. Glucocorticoid-induced
13 osteoporosis in patients with sarcoidosis. *Am J Med Sci* 2003;**325**:1-6.
14
15
- 16 14. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly:
17 consequences for bone loss and fractures and therapeutic implications. *Endocr Rev*
18 2001;**22**:477-501.
19
20
- 21 15. Montemurro L, Fraioli P, Rizzato G. Bone loss in untreated longstanding sarcoidosis.
22 *Sarcoidosis* 1991;**8**:29-34.
23
24
- 25 16. Rottoli P, Gonnelli S, Silitro S, Zacchei F, Fabbrini D, Gennari C, et al. Alterations in
26 calcium metabolism and bone mineral density in relation to the activity of sarcoidosis.
27 *Sarcoidosis* 1993;**10**:161-2.
28
29
- 30 17. Hamada K, Nagai S, Tsutsumi T, Izumi T. Bone mineral density and vitamin D in
31 patients with sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 1999;**16**:219-23.
32
33
- 34 18. Sipahi S, Tuzun S, Ozaras R, Calis HT, Ozaras N, Tuzun F, et al. Bone mineral
35 density in women with sarcoidosis. *J Bone Miner Metab* 2004;**22**:48-52.
36
37
- 38 19. Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess
39 and manage. *Semin Respir Crit Care Med* 2010;**31**:474-84.
40
41
- 42 20. Sharma OP. Vitamin D and sarcoidosis. *Curr Opin Pulm Med* 2010;**16**:487-8.
43
44
- 45 21. Sage RJ, Rao DS, Burke RR, Lim HW. Preventing vitamin D toxicity in patients with
46 sarcoidosis. *J Am Acad Dermatol* 2011;**64**:795-6.
47
48
49
50
51
52
53
54
55
56
57

- 1
- 2
- 3 22. Sweiss NJ, Lower EE, Korsten P, Niewold TB, Favus MJ, Baughman RP. Bone health
- 4 issues in sarcoidosis. *Curr Rheumatol Rep* 2011;**13**:265-72.
- 5
- 6
- 7 23. Angus RM, Sambrook PN, Pocock NA, Eisman JA. A simple method for assessing
- 8 calcium intake in Caucasian women. *J Am Diet Assoc* 1989;**89**:209-14.
- 9
- 10
- 11 24. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;**357**:266-81.
- 12
- 13
- 14 25. Sattar N, Welsh P, Panarelli M, Forouhi NG. Increasing requests for vitamin D
- 15 measurement: costly, confusing, and without credibility. *Lancet* 2012;**379**:95-6.
- 16
- 17
- 18 26. Bolland MJ, Grey A, Davidson JS, Cundy T, Reid IR. Should measurement of vitamin
- 19 D and treatment of vitamin D insufficiency be routine in New Zealand? *N Z Med J*
- 20 2012;**125**:83-91.
- 21
- 22
- 23 27. Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. *BMJ*
- 24 2010;**340**:b5664.
- 25
- 26
- 27
- 28 28. Murad MH, Elamin KB, Abu Elnour NO, Elamin MB, Alkatib AA, Fatourechi MM,
- 29 et al. Clinical review: The effect of vitamin D on falls: a systematic review and meta-
- 30 analysis. *J Clin Endocrinol Metab* 2011;**96**:2997-3006.
- 31
- 32
- 33 29. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D
- 34 analogues for preventing fractures associated with involutional and post-menopausal
- 35 osteoporosis. *Cochrane Database Syst Rev* 2009:CD000227.
- 36
- 37
- 38 30. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz
- 39 JP, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-
- 40 analysis. *J Clin Endocrinol Metab* 2011;**96**:1931-42.
- 41
- 42
- 43 31. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D With or Without
- 44 Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-
- 45 analysis for the U.S. Preventive Services Task Force. *Ann Intern Med* 2011;**155**:827-
- 46 38.
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 32. Carter GD. 25-Hydroxyvitamin D assays: the quest for accuracy. Clin Chem
4
5 2009;**55**:1300-2.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Baseline characteristics

	Vitamin D n=13	Placebo n=14
Age (y)	56 (10)	57 (9)
Female	10 (77)	9 (64)
Ethnicity		
European	10 (77)	9 (64)
Indian	1 (8)	3 (21)
Other	1 (8)	2 (14)
Weight (kg)	75 (19)	72 (13)
Dietary calcium intake (mg/d)	730 (670)	660 (330)
Smoking status		
Current	3 (23)	0 (0)
Never Smoked	8 (63)	9 (64)
Glucorticoid use		
Past oral use	7 (54)	9 (64)
Current oral use	1 (8)	0 (0)
Current inhaled use	6 (46)	1 (7)
Sarcoidosis extent		
Pulmonary involvement	11 (85)	8 (57)
Extra-pulmonary involvement	6 (46)	7 (50)
Chest radiograph stage at baseline		
Stage 0	1 (10)	6 (46)
Stage 1	1 (10)	1 (8)
Stage 2	1 (10)	0 (0)
Stage 3	3 (30)	4 (31)
Stage 4	4 (40)	2 (15)
Bone density (g/cm ²)		
Lumbar spine	1.16 (0.19)	1.13 (0.11)
T score	-0.2 (1.6)	-0.6 (0.9)
Total hip	0.95 (0.11)	0.93 (0.11)
T score	-0.6 (0.9)	-0.8 (0.9)
Femoral neck	0.89 (0.13)	0.91 (0.09)
T score	-1.2 (1.0)	-0.9 (0.7)
Total body	1.15 (0.10)	1.11 (0.07)
Adjusted serum calcium (mmol/L)	2.24 (0.06)	2.26 (0.12)
Serum phosphate (mmol/L)	1.23 (0.15)	1.06 (0.17)
Serum creatinine (mmol/L)	74 (14)	77 (12)
24 hr urine calcium (mmol/d)	4.6 (3.4)	6.6 (5.2)

Screening 25 hydroxyvitamin D (nmol) ^a	35 (12)	38 (9)
Baseline 25 hydroxyvitamin D (nmol) ^a	40 (17)	45 (17)
1,25 dihydroxyvitamin D (pmol/L)	109 (34)	116 (25)
Parathyroid hormone (pmol/L)	4.0 (1.6)	4.9 (2.0)
P1NP (ug/L)	37 (12)	40 (15)
β-CTX (ng/L)	310 (130)	360 (210)

^a 25-hydroxyvitamin D were measured at the screening study visit using a Diasorin assay, while the baseline 25-hydroxyvitamin D at the first study visit (average 3 weeks later) were stored frozen until the end of the study and then measured with a liquid chromatography tandem mass spectrometry assay (see text). Data are mean (SD) or n (%). Abbreviations: P1NP- serum procollagen type-I N-terminal propeptide; β-CTX - serum β-C-terminal telopeptide of type I collagen.

Table 2: Time course of hypercalcaemia in patient randomized to vitamin D supplements

Week ^a	Dietary calcium (mg/d)	Serum calcium ^b (mmol/L)	Serum phosphate (mmol/L)	Serum creatinine (μmol/L)	24h urine calcium (mmol/d)	25OHD (nmol/L)	1,25OHD (pmol/L)	PTH (pmol/L)
0	460	2.26	1.24	76	4.2	18	77	2.3
2		2.36	1.28	74				
4		2.48	1.57	83	14.4	69	218	0.9
6		2.88	1.55	112				
7		2.87	1.31	125				
8		2.65	1.45	124				
12		2.46	1.23	93				
16		2.22	1.14	75				
26		2.28	1.04	71		31	81	2.2
52		2.27	1.11	78	6.7	41	77	2.1

^a study treatment was stopped at 6 weeks when hypercalcaemia was recognised. The last dose was taken at week 5, and five 50,000 IU doses of cholecalciferol were taken over 5 weeks.

^b albumin-adjusted serum calcium.

Abbreviations : 25OHD 25-hydroxyvitamin D, 1,25OHD 1,25-dihydroxyvitamin D, PTH-parathyroid hormone.

1
2
3 Figure 1: flow of participants
4
5
6

7 Figure 2: The effect of vitamin D supplementation on 25-hydroxyvitamin D and 1,25-
8 dihydroxyvitamin D levels. Data are mean and 95% confidence interval. P values are for
9 time-by-treatment interaction. Asterisks indicate significant between-groups differences at
10 individual points.
11
12
13
14
15
16
17

18 Figure 3: The effect of vitamin D supplementation on albumin-adjusted serum calcium and
19 24h urine calcium levels. Data are mean and 95% confidence interval. P values are for time-
20 by-treatment interaction.
21
22
23
24
25
26

27 Figure 4: The effect of vitamin D supplementation on bone turnover markers and serum
28 parathyroid (PTH). Data are mean and 95% confidence interval. P values are for time-by-
29 treatment interaction. Abbreviations: Procollagen type-I N-terminal propeptide: P1NP; β -C-
30 terminal telopeptide of type I collagen: β -CTx
31
32
33
34
35
36
37

38 Figure 5: The effect of vitamin D supplementation on bone mineral density (BMD). Data are
39 mean and 95% confidence interval for the percentage change from baseline adjusted for
40 baseline BMD. P values are for time-by-treatment interaction.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: flow of participants
106x76mm (600 x 600 DPI)

View only




Figure 2: The effect of vitamin D supplementation on 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels. Data are mean and 95% confidence interval. P values are for time-by-treatment interaction. Asterisks indicate significant between-groups differences at individual points.
172x296mm (600 x 600 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3: The effect of vitamin D supplementation on albumin-adjusted serum calcium and 24h urine calcium levels. Data are mean and 95% confidence interval. P values are for time-by-treatment interaction. 139x175mm (600 x 600 DPI)




Figure 5: The effect of vitamin D supplementation on bone mineral density (BMD). Data are mean and 95% confidence interval for the percentage change from baseline adjusted for baseline BMD. P values are for time-by-treatment interaction.
86x62mm (600 x 600 DPI)

Title: Randomized controlled trial of vitamin D supplementation in sarcoidosis.

Running title: Vitamin D supplementation and sarcoidosis

Authors:

Mark J Bolland, MBChB, PhD,¹
Margaret L Wilsher, MD,^{1,2}
Andrew Grey, MD,¹
Anne M Horne, MBChB,¹
Sheryl Fenwick, BAppSc¹
Greg D Gamble, MSc¹
Ian R Reid, MD,¹

Affiliation:

¹Department of Medicine, University of Auckland, Private Bag 92 019, Auckland 1142, New Zealand; ² Green Lane Respiratory Services, Auckland District Health Board, Private Bag 92024, Auckland 1142, New Zealand

Address for correspondence/reprints:

Mark Bolland
Bone and Joint Research Group,
Department of Medicine, University of Auckland
Private Bag 92 019, Auckland 1142, New Zealand
Email: m.bolland@auckland.ac.nz
Ph 64 9 373 7999
Fax 64 9 373 7677

Funding:

This study was funded by the Health Research Council of New Zealand, and the Greenlane Research and Education Fund.

Word counts:

Text only: 2433
Abstract: 275
Figures: 5
Tables: 2

Disclosure: All the authors state that they have no conflicts of interest.

Key words: vitamin D, hypercalcaemia, sarcoidosis, bone turnover, bone mineral density

Trial registration: This trial is registered at the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au). The registration number is ACTRN12607000364471, date of registration 5/7/2007.

Article focus:

- The effect of vitamin D supplementation on calcium homeostasis and skeletal health in sarcoidosis
- A randomized, placebo-controlled trial of vitamin D supplements in 27 normocalcaemic patients with sarcoidosis and 25-hydroxyvitamin D <50nmol/L

Key messages:

- Vitamin D supplementation had no effect on serum or urine calcium, bone turnover markers or bone mineral density over 12 months, but caused 1 case of significant hypercalcaemia.
- This clinical trial suggests that vitamin D supplements are not beneficial and may be harmful for patients with sarcoidosis and mildly low vitamin D levels.

Limitations:

- The study had limited power to detect small differences in bone density and bone turnover markers.
- Few participants had 25-hydroxyvitamin D levels < 25 nmol/L, and therefore the findings may not apply to individuals with very low vitamin D levels.

Abstract**Objectives:**

The role vitamin D intake/production plays in sarcoidosis-associated hypercalcaemia is uncertain. However, authoritative reviews have recommended avoiding sunlight exposure and vitamin D supplements, which might lead to adverse skeletal outcomes from vitamin D insufficiency. We investigated the effects of vitamin D supplementation on surrogate measures of skeletal health in patients with sarcoidosis and vitamin D insufficiency.

Design:

Randomized, placebo-controlled trial

Setting: Clinical research centre

Participants: 27 normocalcaemic patients with sarcoidosis and 25-hydroxyvitamin D (25OHD) <50nmol/L.

Intervention: 50,000IU weekly cholecalciferol for 4 weeks, then 50,000IU monthly for 11 months) or placebo

Primary and secondary outcome measures: The primary endpoint was the change in serum calcium over 12 months, and secondary endpoints included measurements of calcitropic hormones, bone turnover markers, and bone mineral density (BMD).

Results

1
2
3 The mean age of participants was 57y and 70% were female. The mean (SD) screening
4
5 25OHD was 35(12) and 38(9) nmol/L in the treatment and control groups, respectively.
6
7 Vitamin D supplementation increased 25OHD to 94 nmol/L after 4 weeks, 84 nmol/L at 6
8
9 months, and 78 nmol/L at 12 months, while levels remained stable in the control group. 1,25
10
11 dihydroxyvitamin D levels were significantly different between the groups at 4 weeks, but not
12
13 at 6 or 12 months. There were no between-groups differences in albumin-adjusted serum
14
15 calcium, 24h urine calcium, markers of bone turnover, parathyroid hormone, or BMD over
16
17 the trial. One participant developed significant hypercalcaemia after 6 weeks (total
18
19 cholecalciferol dose 250,000IU).
20
21
22
23
24

25 **Conclusions**

26
27 In patients with sarcoidosis and 25OHD <50nmol/L, vitamin D supplements did not alter
28
29 average serum calcium or urine calcium, but had no benefit on surrogate markers of skeletal
30
31 health and caused one case of significant hypercalcaemia.
32
33
34
35

36 **Trial registration:** This trial is registered at the Australian New Zealand Clinical Trials
37
38 Registry (www.anzctr.org.au). The registration number is ACTRN12607000364471, date of
39
40 registration 5/7/2007.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction:

Hypercalcaemia occurs commonly in sarcoidosis, with an estimated prevalence of 4-11%. [1,2] Hypercalcaemia results from dysregulated production of 1,25-dihydroxyvitamin D (1,25OHD) by activated macrophages in granulomata. [3] Although the mechanism of hypercalcaemia is known, the role of vitamin D intake and production is less certain. On one hand, cases of hypercalcaemia and sarcoidosis precipitated by sunlight exposure or vitamin D supplements have been reported, [4-8] and there is seasonal variation in 1,25OHD levels [9] and the prevalence of hypercalcaemia. [7, 9, 10] These findings suggest that increases in 25-hydroxyvitamin D (25OHD) levels through sunlight exposure or vitamin D intake contribute to the hypercalcaemia. On the other hand, studies have reported no correlation between 25OHD, 1,25OHD, and serum calcium, [11] historical studies of treatment with very large doses of vitamin D (target 100,000 IU/d for 5-212 days) produced hypercalcaemia in only 4/24 patients, [12] and patients with sarcoidosis and glucocorticoid-induced osteoporosis commonly take vitamin D supplements without developing hypercalcaemia. [13] Furthermore, countries at higher latitudes do not have consistently lower prevalence of hypercalcaemia in sarcoidosis than countries closer to the equator, [1] and prevalence of hypercalcaemia in sarcoidosis is similar in countries with and without dietary vitamin D fortification. [6] These findings suggest that vitamin D intake and production are not the sole causes of hypercalcaemia in sarcoidosis.

Despite the conflicting evidence over the role of vitamin D intake/production in sarcoidosis-associated hypercalcaemia, several authoritative reviews have recommended avoidance of sunlight exposure and vitamin D supplements. [6-8] Adopting such recommendations is likely to lead to vitamin D insufficiency, which is associated with a number of adverse skeletal outcomes including secondary hyperparathyroidism, increased bone turnover, low bone

1
2
3 mineral density (BMD) and increased risk of fracture.[14] There is a high prevalence of low
4
5 BMD in cross-sectional studies of patients with sarcoidosis,[7 ,13 ,15-18] and glucocorticoid
6
7 use is common and well known to have adverse skeletal effects. Thus, it is possible that
8
9 treatment recommendations of sarcoidosis may worsen skeletal health by inadvertently
10
11 promoting vitamin D insufficiency.
12
13

14
15
16 There has been recent interest in the effects of vitamin D supplements in patients with
17
18 sarcoidosis.[19-22] We have carried out a randomized controlled trial to determine the effects
19
20 of vitamin D supplementation [on surrogate measures of skeletal health](#) in patients with
21
22 sarcoidosis and vitamin D insufficiency.
23
24
25
26

27 **Methods:**

28 Participants:

29
30
31 Patients with sarcoidosis attending the interstitial lung disease clinic at our hospital were invited
32
33 to participate. Newspaper advertisements were also placed. Potential participants were eligible if
34
35 they had sarcoidosis diagnosed by biopsy and/or typical pattern on high resolution computed
36
37 tomography and screening 25OHD <50 nmol/L, but were excluded if they had serum creatinine
38
39 >150 umol/L, nephrocalcinosis, albumin-adjusted serum calcium >2.55 mmol/L, concurrent
40
41 major systemic illness, or BMD T score <-2.5 at the spine or hip. Participants were recruited
42
43 between September 2007 and December 2010. The flow of participants is shown in Figure 1.
44
45
46
47
48

49 Protocol

50
51
52 Participants were randomized to receive either 50,000 IU of cholecalciferol or placebo weekly
53
54 for four weeks followed by 50,000 IU cholecalciferol or placebo every month for 11 months.
55
56 Patients were asked to continue their usual diet to maintain their dietary calcium intake in
57
58
59
60

1
2
3 accordance with locally recommended practice. Calcium supplements were not administered.
4
5 Treatment allocations were randomized by the study statistician, using a variable block size
6
7 schedule, based on computer-generated random numbers. Study medication was dispensed into
8
9 identical bottles and labelled with participant numbers by a staff member not otherwise involved
10
11 in the study. To ensure masking, only the statistician and this staff member had access to
12
13 treatment allocation, and neither had contact with participants. All other study personnel and
14
15 participants were blinded to treatment allocation throughout. The study received ethical
16
17 approval from the Northern X regional ethics committee and the trial was registered with the
18
19 Australian New Zealand Clinical Trials Registry, ACTRN12607000364471. All participants
20
21 gave written, informed consent.
22
23
24
25

26
27 The primary endpoint was the change in serum calcium over 12 months with vitamin D
28
29 supplementation. Secondary endpoints were the change in urine calcium, change in markers of
30
31 bone turnover, and change in BMD over 12 months. It was planned to recruit 40 participants, for
32
33 which the study had >80% power ($\alpha = 0.05$) to detect a difference in serum calcium of 0.10
34
35 mmol/L between groups. Recruitment was stopped after more than 3y when 27 participants were
36
37 recruited.
38
39
40
41

42 43 Measurements:

44
45 At baseline, every 2 weeks for 8 weeks, then at 12, 16, 26, 39, and 52 weeks, fasting blood
46
47 and second-voided morning urine samples were collected. Samples for calcitropic hormones
48
49 and bone turnover markers were stored at -70°C until they were batch-analyzed. At baseline,
50
51 4, 26, and 52 weeks, 24h urine samples were collected. The following assays were used: the
52
53 screening 25OHD was measured by radioimmunoassay (RIA) (DiaSorin, Stillwater, MN), but
54
55 all 25OHD samples from the study including the baseline sample were measured by liquid
56
57
58
59
60

1
2
3 chromatography- tandem mass spectrometry (LC-MS/MS) (ABSciex API 4000); 1,25OHD
4
5 by RIA (IDS, Tyne and Wear, UK), serum parathyroid hormone (PTH) by
6
7 electrochemiluminescence immunoassay (E170, Roche Diagnostics, Indianapolis, IN); serum
8
9 procollagen type-I N-terminal propeptide (P1NP) and serum β -C-terminal telopeptide of type I
10
11 collagen (CTX) by the Roche Elecsys 2010 platform (Roche Diagnostics, Indianapolis, IN).
12
13
14 BMD was measured every 6 months at the lumbar spine, proximal femur and total body using a
15
16 GE Prodigy dual-energy x-ray absorptiometer (DXA) (GE Lunar, Madison WI). Daily calcium
17
18 intake was assessed at baseline using a validated questionnaire.[23]
19
20

21 22 23 Statistics:

24
25 Baseline differences between groups for continuous variables were assessed using Student's t-
26
27 test, and for categorical variables using the Chi-Square test. All analyses were carried out on an
28
29 intention-to-treat basis. A mixed models approach to repeated measures **with an unstructured**
30
31 **covariance structure** was used to examine the time course of response in the treatment and
32
33 control arms for serum calcium, urine calcium, calcitropic hormones, bone turnover markers and
34
35 BMD measurements by fitting main and treatment-by-time interaction effects. Post-hoc
36
37 comparisons between groups at individual time points were explored using the method of Tukey.
38
39 BMD data were analyzed using raw data, although results are presented as percentage change
40
41 from baseline adjusted for baseline between-groups differences, for ease of interpretation. All
42
43 tests were two-tailed and **hypothesis tests were deemed significant for** $P < 0.05$. All statistical
44
45 analyses were carried out using the SAS software package (SAS Institute, Cary, NC version 9.2)
46
47
48
49
50

51 52 **Results:**

53
54 The baseline characteristics of the two groups were similar (Table 1). The mean (range) 25OHD
55
56 at the study screening visit was 35 (14-48) nmol/L in the treatment group, and 38 (12-49)
57
58
59
60

1
2
3 nmol/L in the controls. The baseline 25OHD measurements from the first study visit (average 3
4 weeks after screening 25OHD) that were stored and then measured at the end of the study using
5 a different assay were slightly higher than the screening 25OHD in both groups (Table 1).
6
7

8
9 Vitamin D supplementation led to an immediate increase in 25OHD levels, and a sustained
10 difference between the groups that persisted throughout the trial ($P < 0.001$) (Figure 2). There was
11 also an immediate increase in 1,25OHD levels in response to vitamin D supplementation, but
12 this did not persist. While the between-groups differences over the trial were statistically
13 significant ($P = 0.007$), by the end of the trial 1,25OHD levels were similar in both groups (Figure
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3 shows that vitamin D supplements had no effect on either average albumin-adjusted serum calcium ($P = 0.46$) or 24h urine calcium levels ($P = 0.10$) throughout the trial. There were no between-group differences at any time point in participants with 24h urine calcium > 10 mmol/day (baseline vitamin D vs control- 1 vs. 4; 4 weeks- 4 vs. 4; 16 weeks 1 vs. 2; 52 weeks – 3 vs. 2). One participant in the vitamin D group and none in the control group had sustained hypercalcaemia with 24h urine calcium > 10 mmol/day in all 3 visits during follow-up. One participant developed hypercalcaemia during the trial- a 51y old female, diagnosed with sarcoidosis 2y prior to study entry, with bilateral hilar lymphadenopathy, liver, and lung involvement. She was taking inhaled glucocorticoids at study entry but no other medication. She was assigned to vitamin D treatment and Table 2 shows that hypercalcaemia was recognized at 6 weeks, by which time she had taken five 50,000 IU doses of cholecalciferol. She was vitamin D deficient at baseline, and treatment increased her 25OHD level to 69 nmol/L. There was a marked increase in 1,25OHD, 24h urine calcium, serum phosphate, and creatinine levels and suppression of PTH levels following vitamin D supplementation, but she remained asymptomatic throughout. No further study medication was taken and the biochemical

1
2
3 abnormalities resolved without specific treatment by week 16 of the trial. When this participant
4
5 was excluded from the analyses for serum calcium and 24h urine calcium, the results did not
6
7 change substantially except there was no visible rise in the average albumin-adjusted serum
8
9 calcium at 6 and 8 weeks in the vitamin D group (data not shown).
10

11
12
13
14 The effect of vitamin D supplements on bone turnover markers and PTH are shown in Figure 4
15
16 and on BMD in Figure 5. Vitamin D supplementation had no effect on any of these variables
17
18 ($P>0.16$ for all variables).
19

20
21
22
23 Other than the 1 participant treated with vitamin D who developed hypercalcaemia (proportion
24
25 8%, 95% confidence interval 1-33%), there were no other adverse events potentially related to
26
27 treatment during the trial. 1 participant (randomized to vitamin D) required prolonged treatment
28
29 with oral glucocorticoids, and 1 participant (randomized to placebo) received a single infusion of
30
31 zoledronic acid at 11 months, because of an underlying neurological disorder that had led to an
32
33 increased risk of falls and fracture.
34
35
36
37

38 **Discussion:**

39
40 Vitamin D supplementation of patients with sarcoidosis and vitamin D insufficiency did not alter
41
42 average serum calcium or urine calcium levels, but also did not affect BMD or markers of bone
43
44 turnover, and caused one case of significant hypercalcaemia. 25OHD levels were in a range
45
46 many experts consider sub-optimal at baseline (average <50 nmol/L) and vitamin D
47
48 supplementation led to average 25OHD levels of >75 nmol/L throughout the trial, levels
49
50 generally considered to indicate adequate vitamin D status. Thus, our findings of an absence of
51
52 benefit from vitamin D supplements, together with infrequent but significant hypercalcaemia,
53
54
55
56
57
58
59
60

1
2
3 suggest that there is little indication for vitamin D supplements in patients with sarcoidosis and
4
5 vitamin D insufficiency.
6
7

8
9
10 Recent research has linked low 25OHD levels with numerous adverse non-skeletal
11
12 outcomes.[24] This information, when added to the existing data linking low 25OHD levels with
13
14 adverse skeletal outcomes,[14] has lead to renewed interest in the role of vitamin D in health. In
15
16 clinical practice, there has been a large increase in measurement of 25OHD[25 ,26] and calls for
17
18 widespread vitamin D supplementation.[27] However, these associations between low vitamin D
19
20 status and adverse health outcomes have been generated from observational studies which
21
22 cannot determine causality. There are now a growing number of randomized controlled trials
23
24 that have not shown benefits from vitamin D supplements on a wide range of endpoints. Thus,
25
26 meta-analyses of such trials have shown no benefit of vitamin D supplementation (when used
27
28 without co-administered calcium supplements) on falls,[28] fractures,[29] mortality,[30]
29
30 cardiovascular events,[30] and cancer.[31] In our study, which was powered to assess serum
31
32 calcium rather than BMD effects, we did not find evidence for benefit of vitamin D supplements
33
34 on surrogate markers of skeletal health in a group of patients with sarcoidosis who had mildly
35
36 low 25OHD levels, consistent with these findings.
37
38
39
40
41
42

43 The mechanism of hypercalcaemia in sarcoidosis is well described. Extra-renal production of
44
45 1,25OHD in activated macrophages in granulomata leads to increased intestinal calcium
46
47 absorption and increased bone resorption which collectively produce hypercalcaemia.[3] It is
48
49 unclear whether circulating 25OHD levels are implicated in causing hypercalcaemia, with some
50
51 evidence supporting [4-10] and some not supporting [1 ,6 ,11-13] each viewpoint, as discussed
52
53 earlier. Our study tends to support the former view for two reasons: firstly, one patient developed
54
55 significant hypercalcaemia within a short time of starting vitamin D supplements, and there was
56
57
58
59
60

1
2
3 prompt resolution of the hypercalcaemia without other treatment after the supplements were
4 stopped. Secondly, in the entire cohort there was a rapid increase in 1,25OHD with vitamin D
5 supplements, although the increase did not persist. Both pieces of data suggest that abrupt
6 changes in 25OHD can increase 1,25OHD, and in a minority of patients this can cause
7 hypercalcaemia. The characteristics that predispose to the development of hypercalcaemia
8 remain unclear. It is possible that increasing 25OHD more slowly using small, incrementally
9 increasing doses of vitamin D, may avoid this complication, but this would need to be tested in
10 closely monitored clinical trials.
11
12
13
14
15
16
17
18
19

20
21
22 Our study has several limitations. It is a small study and therefore may be at risk of Type II error.
23 We carried out simulations to explore what effect sizes could have been statistically significant
24 in this study. We simulated an increased effect size in the treatment group (without varying data
25 in the placebo group or the sample size) in the models used in the study analyses. A difference
26 between the groups at 1y of 0.06 mmol/L in serum calcium, the primary endpoint, would have
27 reached conventional statistical significance. This is 60% of the value used in the study power
28 calculation (0.1 mmol/L) that we considered to be clinically relevant when designing the study.
29 Similarly, the corresponding between-groups differences that would have reached statistical
30 significance for the other main endpoints were: 2.4 pmol/L for PTH, 7 µg/L for P1NP, 140 ng/L
31 for CTX, and 0.5% - 1.9% for BMD, depending on site. Differences below these amounts would
32 be of questionable clinical relevance. Thus, while small, the study did have more than adequate
33 power to detect clinically relevant differences. A second limitation is regarding the screening
34 vitamin D measurement. All participants had 25OHD <50 nmol/L at the screening visit
35 measured using a Diasorin RIA. All study samples for 25OHD were frozen and then assayed in
36 a single batch at another laboratory using an LC-MS/MS assay. The 25OHD levels measured
37 using LC-MS/MS were on average slightly higher than those measured using the Diasorin
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 immunoassay, and 9/27 participants had 25OHD > 50 nmol/L at the baseline visit. Variation
4
5 between results from different 25OHD assays is well-described, and while LC-MS/MS is
6
7 usually considered the gold standard, both immunoassays and LC-MS/MS have limitations.[32]
8
9 Few participants had 25OHD < 25 nmol at baseline, thus our results may not apply to
10
11 individuals with very low 25OHD levels.
12
13

14
15
16 In summary, we did not find evidence of benefits on surrogate markers of skeletal health from
17
18 vitamin D supplementation in patients with sarcoidosis and vitamin D insufficiency. However,
19
20 there was evidence of harm with one case of significant hypercalcaemia. The absence of benefit
21
22 together with the risk of infrequent but significant adverse effects suggests that there is little
23
24 indication for vitamin D supplements in patients with sarcoidosis and vitamin D levels in the
25
26 range in this study (12 – 49 nmol/L).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Funding:

This study was funded by the Health Research Council of New Zealand, and the Greenlane Research and Education Fund. The sponsors of the study had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Disclosure: All the authors state that they have no conflicts of interest.

Contributorship:

MB, AG, AH, IR, and MW designed the study. SF and AH ran the study. MB and GG carried out the statistical analyses. MB drafted the article. All authors critically reviewed the draft manuscript and approved the final version. MB is the guarantor of the article.

Data sharing:

There are no additional data available.

References

1. James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. *Ann N Y Acad Sci* 1976;**278**:321-34.
2. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Jr., Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. *Am J Respir Crit Care Med* 2001;**164**:1885-9.
3. Singer FR, Adams JS. Abnormal calcium homeostasis in sarcoidosis. *N Engl J Med* 1986;**315**:755-7.
4. Bell NH, Gill JR, Jr., Bartter FC. On the Abnormal Calcium Absorption in Sarcoidosis. Evidence for Increased Sensitivity to Vitamin D. *Am J Med* 1964;**36**:500-13.
5. Sandler LM, Winearls CG, Fraher LJ, Clemens TL, Smith R, O'Riordan JL. Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3. *Q J Med* 1984;**53**:165-80.
6. Sharma OP. Vitamin D, calcium, and sarcoidosis. *Chest* 1996;**109**:535-9.
7. Rizzato G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. *Thorax* 1998;**53**:425-9.
8. Conron M, Young C, Beynon HL. Calcium metabolism in sarcoidosis and its clinical implications. *Rheumatology (Oxford)* 2000;**39**:707-13.
9. Bonnema SJ, Moller J, Marving J, Kvetny J. Sarcoidosis causes abnormal seasonal variation in 1,25-dihydroxy-cholecalciferol. *J Intern Med* 1996;**239**:393-8.
10. Taylor RL, Lynch HJ, Jr., Wysor WG, Jr. Seasonal influence of sunlight on the hypercalcemia of sarcoidosis. *Am J Med* 1963;**34**:221-7.

- 1
2
3 11. Alberts C, van den Berg H. Calcium metabolism in sarcoidosis. A follow-up study
4 with respect to parathyroid hormone and vitamin D metabolites. *Eur J Respir Dis*
5 1986;**68**:186-94.
6
7
- 8
9 12. Larsson LG, Liljestrand A, Wahlund H. Treatment of sarcoidosis with calciferol. *Acta*
10 *Med Scand* 1952;**143**:281-87.
11
- 12 13. Adler RA, Funkhouser HL, Petkov VI, Berger MM. Glucocorticoid-induced
13 osteoporosis in patients with sarcoidosis. *Am J Med Sci* 2003;**325**:1-6.
14
15
- 16 14. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly:
17 consequences for bone loss and fractures and therapeutic implications. *Endocr Rev*
18 2001;**22**:477-501.
19
20
- 21 15. Montemurro L, Fraioli P, Rizzato G. Bone loss in untreated longstanding sarcoidosis.
22 *Sarcoidosis* 1991;**8**:29-34.
23
24
- 25 16. Rottoli P, Gonnelli S, Silitro S, Zacchei F, Fabbrini D, Gennari C, et al. Alterations in
26 calcium metabolism and bone mineral density in relation to the activity of sarcoidosis.
27 *Sarcoidosis* 1993;**10**:161-2.
28
29
- 30 17. Hamada K, Nagai S, Tsutsumi T, Izumi T. Bone mineral density and vitamin D in
31 patients with sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 1999;**16**:219-23.
32
33
- 34 18. Sipahi S, Tuzun S, Ozaras R, Calis HT, Ozaras N, Tuzun F, et al. Bone mineral
35 density in women with sarcoidosis. *J Bone Miner Metab* 2004;**22**:48-52.
36
37
- 38 19. Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess
39 and manage. *Semin Respir Crit Care Med* 2010;**31**:474-84.
40
41
- 42 20. Sharma OP. Vitamin D and sarcoidosis. *Curr Opin Pulm Med* 2010;**16**:487-8.
43
44
- 45 21. Sage RJ, Rao DS, Burke RR, Lim HW. Preventing vitamin D toxicity in patients with
46 sarcoidosis. *J Am Acad Dermatol* 2011;**64**:795-6.
47
48
49
50
51
52
53
54
55
56
57

- 1
- 2
- 3 22. Sweiss NJ, Lower EE, Korsten P, Niewold TB, Favus MJ, Baughman RP. Bone health
- 4 issues in sarcoidosis. *Curr Rheumatol Rep* 2011;**13**:265-72.
- 5
- 6
- 7 23. Angus RM, Sambrook PN, Pocock NA, Eisman JA. A simple method for assessing
- 8 calcium intake in Caucasian women. *J Am Diet Assoc* 1989;**89**:209-14.
- 9
- 10
- 11 24. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;**357**:266-81.
- 12
- 13
- 14 25. Sattar N, Welsh P, Panarelli M, Forouhi NG. Increasing requests for vitamin D
- 15 measurement: costly, confusing, and without credibility. *Lancet* 2012;**379**:95-6.
- 16
- 17
- 18 26. Bolland MJ, Grey A, Davidson JS, Cundy T, Reid IR. Should measurement of vitamin
- 19 D and treatment of vitamin D insufficiency be routine in New Zealand? *N Z Med J*
- 20 2012;**125**:83-91.
- 21
- 22
- 23 27. Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. *BMJ*
- 24 2010;**340**:b5664.
- 25
- 26
- 27
- 28 28. Murad MH, Elamin KB, Abu Elnour NO, Elamin MB, Alkatib AA, Fatourechi MM,
- 29 et al. Clinical review: The effect of vitamin D on falls: a systematic review and meta-
- 30 analysis. *J Clin Endocrinol Metab* 2011;**96**:2997-3006.
- 31
- 32
- 33 29. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D
- 34 analogues for preventing fractures associated with involutional and post-menopausal
- 35 osteoporosis. *Cochrane Database Syst Rev* 2009:CD000227.
- 36
- 37
- 38 30. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz
- 39 JP, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-
- 40 analysis. *J Clin Endocrinol Metab* 2011;**96**:1931-42.
- 41
- 42
- 43 31. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D With or Without
- 44 Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-
- 45 analysis for the U.S. Preventive Services Task Force. *Ann Intern Med* 2011;**155**:827-
- 46 38.
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 32. Carter GD. 25-Hydroxyvitamin D assays: the quest for accuracy. Clin Chem
4
5 2009;**55**:1300-2.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Baseline characteristics

	Vitamin D n=13	Placebo n=14
Age (y)	56 (10)	57 (9)
Female	10 (77)	9 (64)
Ethnicity		
European	10 (77)	9 (64)
Indian	1 (8)	3 (21)
Other	1 (8)	2 (14)
Weight (kg)	75 (19)	72 (13)
Dietary calcium intake (mg/d)	730 (670)	660 (330)
Smoking status		
Current	3 (23)	0 (0)
Never Smoked	8 (63)	9 (64)
Glucorticoid use		
Past oral use	7 (54)	9 (64)
Current oral use	1 (8)	0 (0)
Current inhaled use	6 (46)	1 (7)
Sarcoidosis extent		
Pulmonary involvement	11 (85)	8 (57)
Extra-pulmonary involvement	6 (46)	7 (50)
Chest radiograph stage at baseline		
Stage 0	1 (10)	6 (46)
Stage 1	1 (10)	1 (8)
Stage 2	1 (10)	0 (0)
Stage 3	3 (30)	4 (31)
Stage 4	4 (40)	2 (15)
Bone density (g/cm ²)		
Lumbar spine	1.16 (0.19)	1.13 (0.11)
T score	-0.2 (1.6)	-0.6 (0.9)
Total hip	0.95 (0.11)	0.93 (0.11)
T score	-0.6 (0.9)	-0.8 (0.9)
Femoral neck	0.89 (0.13)	0.91 (0.09)
T score	-1.2 (1.0)	-0.9 (0.7)
Total body	1.15 (0.10)	1.11 (0.07)
Adjusted serum calcium (mmol/L)	2.24 (0.06)	2.26 (0.12)
Serum phosphate (mmol/L)	1.23 (0.15)	1.06 (0.17)
Serum creatinine (mmol/L)	74 (14)	77 (12)
24 hr urine calcium (mmol/d)	4.6 (3.4)	6.6 (5.2)

Screening 25 hydroxyvitamin D (nmol) ^a	35 (12)	38 (9)
Baseline 25 hydroxyvitamin D (nmol) ^a	40 (17)	45 (17)
1,25 dihydroxyvitamin D (pmol/L)	109 (34)	116 (25)
Parathyroid hormone (pmol/L)	4.0 (1.6)	4.9 (2.0)
P1NP (ug/L)	37 (12)	40 (15)
β-CTX (ng/L)	310 (130)	360 (210)

^a 25-hydroxyvitamin D were measured at the screening study visit using a Diasorin assay, while the baseline 25-hydroxyvitamin D at the first study visit (average 3 weeks later) were stored frozen until the end of the study and then measured with a liquid chromatography tandem mass spectrometry assay (see text). Data are mean (SD) or n (%). Abbreviations: P1NP- serum procollagen type-I N-terminal propeptide; β-CTX - serum β-C-terminal telopeptide of type I collagen.

Table 2: Time course of hypercalcaemia in patient randomized to vitamin D supplements

Week ^a	Dietary calcium (mg/d)	Serum calcium ^b (mmol/L)	Serum phosphate (mmol/L)	Serum creatinine (μmol/L)	24h urine calcium (mmol/d)	25OHD (nmol/L)	1,25OHD (pmol/L)	PTH (pmol/L)
0	460	2.26	1.24	76	4.2	18	77	2.3
2		2.36	1.28	74				
4		2.48	1.57	83	14.4	69	218	0.9
6		2.88	1.55	112				
7		2.87	1.31	125				
8		2.65	1.45	124				
12		2.46	1.23	93				
16		2.22	1.14	75				
26		2.28	1.04	71		31	81	2.2
52		2.27	1.11	78	6.7	41	77	2.1

^a study treatment was stopped at 6 weeks when hypercalcaemia was recognised. The last dose was taken at week 5, and five 50,000 IU doses of cholecalciferol were taken over 5 weeks.

^b albumin-adjusted serum calcium.

Abbreviations : 25OHD 25-hydroxyvitamin D, 1,25OHD 1,25-dihydroxyvitamin D, PTH-parathyroid hormone.

1
2
3 Figure 1: flow of participants
4
5
6


7 Figure 2: The effect of vitamin D supplementation on 25-hydroxyvitamin D and 1,25-
8 dihydroxyvitamin D levels. Data are mean and 95% confidence interval. P values are for
9 time-by-treatment interaction. Asterisks indicate significant between-groups differences at
10 individual points.
11
12
13
14
15
16
17

18 Figure 3: The effect of vitamin D supplementation on albumin-adjusted serum calcium and
19 24h urine calcium levels. Data are mean and 95% confidence interval. P values are for time-
20 by-treatment interaction.
21
22
23
24
25
26

27 Figure 4: The effect of vitamin D supplementation on bone turnover markers and serum
28 parathyroid (PTH). Data are mean and 95% confidence interval. P values are for time-by-
29 treatment interaction. Abbreviations: Procollagen type-I N-terminal propeptide: P1NP; β -C-
30 terminal telopeptide of type I collagen: β -CTx
31
32
33
34
35
36
37

38 Figure 5: The effect of vitamin D supplementation on bone mineral density (BMD). Data are
39 mean and 95% confidence interval for the percentage change from baseline adjusted for
40 baseline BMD. P values are for time-by-treatment interaction.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Redundant version of Figure
116x95mm (600 x 600 DPI)

For peer review only